Use of Antidepressants among Patients Diagnosed with Depression: A Scoping Review

Marasine, Nirmal Raj; Sankhi, Sabina; Lamichhane, Rajendra; Marasini, Nabin Raj; Dangi, Nim Bahadur

doi:10.1155/2021/6699028

Cited by 31 publications

(20 citation statements)

References 44 publications

(110 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The World Health Organization has reported that more than 264 million people of all ages suffer from depression globally (GBD 2017 Disease and Injury Incidence and Prevalence Collaborators, 2018). Selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, tricyclic antidepressants, monoamine oxidase inhibitors and some atypical agents are the antidepressant drug groups used in the treatment of depressive disorders today (Marasine et al, 2021). However, a significant proportion of patients with depression either does not respond adequately to these drugs or cannot tolerate various drug-induced side effects (Papp et al, 2021).…”

Section: Introductionmentioning

confidence: 99%

Antidepressant-like effect of tofisopam in mice: A behavioural, molecular docking and MD simulation study

et al. 2022

View full text Add to dashboard Cite

Background: Depression is a disease that affects millions of people worldwide, and the discovery and development of effective and safe antidepressant drugs is one of the important topics of psychopharmacology. Objectives: In this study, it was aimed to investigate the antidepressant-like activity potential of tofisopam, an anxiolytic drug with 2,3-benzodiazepine structure, and to elucidate the pharmacological mechanisms mediating this effect. Methods: The antidepressant-like activity of tofisopam was investigated using tail suspension and modified forced swimming tests. Possible interactions of tofisopam with µ- and δ-opioid receptor subtypes were clarified by pharmacological antagonism, molecular docking and molecular dynamics simulation studies. Results: Tofisopam (50 and 100 mg/kg) significantly shortened the immobility time of mice in both the tail suspension and the modified forced swimming tests. The drug, at the same doses, prolonged the duration of swimming and climbing behaviours measured in modified forced swimming tests. A dosage of 25 mg/kg was ineffective. Mechanistic studies showed that the pretreatment with p-chlorophenylalanine methyl ester (serotonin synthesis inhibitor; 4 consecutive days, 100 mg/kg), α-methyl-para-tyrosine methyl ester (catecholamine synthesis inhibitor; 100 mg/kg), naloxonazine (selective µ-opioid receptor blocker, 7 mg/kg) and naltrindole (a selective δ-opioid receptor blocker, 0.99 mg/kg) abolished the anti-immobility effect induced by the 50 mg/kg dose of tofisopam in the tail suspension tests. Our in silico studies supported the behavioural findings that the antidepressant-like effect of tofisopam is mediated by μ- and δ-opioid receptors. Conclusion: This study is the first to show that tofisopam has antidepressant-like activity mediated by the serotonergic, catecholaminergic and opioidergic systems.

show abstract

Section: Introductionmentioning

confidence: 99%

Antidepressant-like effect of tofisopam in mice: A behavioural, molecular docking and MD simulation study

et al. 2022

View full text Add to dashboard Cite

show abstract

“…SSRIs are still preferred among antidepressant categories. 6 The serotonergic system is highly complex with diverse signaling networks. Serotonin neurotransmitters able to activate the largest number of receptor subtypes and modulates an increasing number of physiological functions such as anxiety, mood, cognition, sleep, and appetite.…”

Section: Introductionmentioning

confidence: 99%

“…Selective serotonin reuptake inhibitors (SSRIs) act on the serotonin transporter (SERT), are the most used among depressive patients, and are also prescribed for anxiety disorders. SSRIs are still preferred among antidepressant categories …”

Section: Introductionmentioning

confidence: 99%

Antidepressant Potential of a Functionalized 3-Selanyl Benzo[b]Furan Compound in Mice: Focus on the Serotonergic System

Rech

Ribeiro

Castro

et al. 2023

ACS Chem. Neurosci.

View full text Add to dashboard Cite

The present study investigated the antidepressant-like potential of a functionalized 3-selanyl benzo[b]furan (SeBZF) in male Swiss mice. To evaluate possible antidepressant-like actions, the compounds SeBZF1–5 (50 mg/kg, intragastric, i.g., route) were acutely screened in the tail suspension tests (TSTs). The compound 3-((4-methoxyphenyl)selanyl)-2-phenylbenzofuran (SeBZF3) was then selected. Dose–response and time–response curves revealed that SeBFZ3 exerts antidepressant-like effects in the TST (5–50 mg/kg) and forced swimming test (FST; 50 mg/kg). Additional tests demonstrated that pretreatment with receptor antagonists WAY100635 (5-HT1A; 0.1 mg/kg, subcutaneous route), ketanserin (5-HT2A/C; 1 mg/kg, intraperitoneal, i.p.), or ondansetron (5-HT3; 1 mg/kg, i.p.) blocked the SeBZF3 antidepressant-like effects (50 mg/kg) in the TST. In addition, the coadministration of subeffective doses of SeBZF3 (1 mg/kg, i.g.) and fluoxetine (a selective serotonin reuptake inhibitor; 5 mg/kg, i.p.) produced synergistic action. A high dose of SeBZF3 (300 mg/kg) did not produce oral acute toxicity. The present results provide evidence for the antidepressant-like action of SeBZF3 and its relative safety, as well as predict the possible interactions with the serotonergic system, aiding in the development of novel options to alleviate psychiatric disabilities.

show abstract

“…It has been widely acknowledged that it takes about at least 6–8 weeks for antidepressants to unfold their action entirely ( 5 ). According to the FDA, SSRIs can increase the risk of suicide in the first 2 weeks of treatment ( 6 ). Besides, it is still controversial that medications have side effects such as weight gain/loss, insomnia, and loss of appetite in treating adolescent depression ( 7 ).…”

Section: Introductionmentioning

confidence: 99%

Early Effects of Repetitive Transcranial Magnetic Stimulation Combined With Sertraline in Adolescents With First-Episode Major Depressive Disorder

Chen

Gao

et al. 2022

Front. Psychiatry

View full text Add to dashboard Cite

BackgroundAdolescence is a period of high incidence for depression. However, there is a limited treatment option for the adolescent depression. For treatment-resistant major depressive disorder, HF-rTMS of the left dorsolateral prefrontal cortex (DLPFC) appears therapeutically effective. The aim of the study is to explore the early effects of repetitive transcranial magnetic stimulation in combination with sertraline in adolescents with first-episode major depressive disorder.MethodsA total of 100 teenage patients with first-episode depression were randomly divided into the study groups. Both groups were treated with sertraline. In addition, the study group was treated with ten sessions of add-on rTMS. The control group was given sertraline only. The depressive symptom and cognitive function were assessed by the Hamilton depression rating scale 17 version (HAMD-17), Children’s Depression Rating Scale-Revised (CDRS-R), Integrated visual and auditory continuous performance test (IVA-CPT), and THINC-it.ResultsThe number of early improvers after 2 weeks of treatment in the study group was statistically significant higher compared to the control group (95.83% vs 73.47%, χ2 = 9.277, P = 0.002). There was significant difference observed in responder rates (62.50% vs. 28.57%, χ2 = 11.262, P = 0.001) or in remission rates (31.25% vs. 6.12%, χ2 = 10.130, P = 0.001) between the two groups at 4 weeks. The score of HAMD-17 and CDRS-R in the study group were significantly lower than the control group (Fgroup = 12.91 vs 10.21, P < 0.05). Attention Quotient (listening, visual and full-scale) attention quotient of IVA-CPT in the study group were higher than those in the control group after treatment, and the differences were statistically significant(P < 0.05). The study group showed higher score in Spotter than the control group after treatment (P < 0.05).DiscussionThis is the most extensive blinded, randomized clinical study to date examining the efficacy of 10-Hz add-on rTMS for first-onset adolescent depression. Our results support that add-on rTMS accelerates the efficacy of the antidepressants, improving the depressive symptoms and cold cognitive function in first-episode adolescent depression.Clinical Trial Registration[www.ClinicalTrials.gov], identifier [ChiCTR2100048534].

show abstract

Use of Antidepressants among Patients Diagnosed with Depression: A Scoping Review

Cited by 31 publications

References 44 publications

Antidepressant-like effect of tofisopam in mice: A behavioural, molecular docking and MD simulation study

Antidepressant-like effect of tofisopam in mice: A behavioural, molecular docking and MD simulation study

Antidepressant Potential of a Functionalized 3-Selanyl Benzo[b]Furan Compound in Mice: Focus on the Serotonergic System

Early Effects of Repetitive Transcranial Magnetic Stimulation Combined With Sertraline in Adolescents With First-Episode Major Depressive Disorder

Contact Info

Product

Resources

About